



# British Pharmacopoeia

British Pharmacopoeia Commission Secretariat

MHRA, 10 South Colonnade  
Canary Wharf, London, E14 4PU  
United Kingdom

[www.pharmacopoeia.com](http://www.pharmacopoeia.com)

Date: 04 October 2018

## TO WHOM IT MAY CONCERN

### **RANITIDINE ORAL SOLUTION BP 2018**

#### **RELATED SUBSTANCES**

There is an error in the solution preparation published in the Related substances test for Ranitidine Oral Solution in the BP 2018 which will be revised at the earliest opportunity.

The solution preparation will be amended as follows:

Carry out the method for liquid chromatography, Appendix III D, using the following solutions.

(1) Prepare a solid phase extraction cartridge containing a C18 sorbent (Sep-Pak C18 cartridges are suitable) by passing 10 mL of methanol followed by 20 mL of 0.5M ammonia through the cartridge; attach the tip of a suitable syringe to the cartridge. Transfer a weighed quantity of the oral solution containing the equivalent of 15 mg of ranitidine to the barrel of the syringe, add 2 mL of 0.5M ammonia to the syringe, insert the plunger and slowly force the mixture through the cartridge, discarding the eluant; repeat with two 4-mL quantities of 0.5M ammonia discarding the eluant. Pass two 5-mL quantities of a mixture of 25 volumes of 0.1M hydrochloric acid and 75 volumes of methanol through the cartridge and collect the eluant; add 40 mL of absolute ethanol to the collected eluant, evaporate the resulting solution to dryness at a temperature not exceeding 30° under reduced pressure and dissolve the residue in 2 mL of water.

(2) Dilute 1 volume of solution (1) to 50 volumes with water.

(3) Dilute 1 volume of solution (1) to 100 volumes with water.

(4) Dilute 1 volume of solution (1) to 200 volumes with water.

(5) Dilute 1 volume of solution (3) to 5 volumes with water.

(6) Dissolve the contents of a vial of ranitidine impurity J EPCRS in 1 mL of solution (1) containing 0.15% w/v of ranitidine hydrochloride BPCRS.

Please accept this as a letter of intent on behalf of the British Pharmacopoeia Commission.

If you have any questions concerning this letter, please do not hesitate to contact the British Pharmacopoeia Secretariat at the address above.

Yours faithfully,

#### **MR JAMES POUND**

*Secretary & Scientific Director*

E-mail: [BPCOM@mhra.gov.uk](mailto:BPCOM@mhra.gov.uk)